Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.49 |
| ▸ | F7 | P08709 | 1/20 | 0.47 |
| ▸ | F3 | P13726 | 1/20 | 0.47 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.47 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.47 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5749311 | 0.84 | — | — | |
| SCHEMBL22426419 | 0.81 | ALDH1A1 (0.56) | ALDH1A1KDM4ESMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL10934521 | 0.81 | ALDH1A1 (0.52) | ALDH1A1KDM4ESMN1; SMN2L3MBTL1KMT2A | |
| Salicylic Acid SCHEMBL810750 | 0.79 | ALDH1A1 (0.70) | ALDH1A1KDM4ESMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL61047 | 0.78 | KDM4E (0.61) | ALDH1A1KDM4ESMN1; SMN2KMT2AMEN1 | |
| SCHEMBL5956989 | 0.77 | ALDH1A1 (0.52) | ALDH1A1KDM4ESMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL9335119 | 0.76 | KDM4E (0.58) | ALDH1A1KDM4ESMN1; SMN2KMT2AMEN1 | |
| SCHEMBL9017594 | 0.76 | KDM4E (0.58) | ALDH1A1KDM4ESMN1; SMN2KMT2AMEN1 | |
| SCHEMBL5573698 | 0.76 | KDM4E (0.58) | ALDH1A1KDM4ESMN1; SMN2KMT2AMEN1 | |
| SCHEMBL16715060 | 0.76 | KDM4E (0.58) | ALDH1A1KDM4ESMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651239-A1 | INTRAVASCULAR DELIVERY OF NON-VIRAL NUCLEIC ACID | Mirus Corporation (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005004879-A1 | INTRAVASCULAR DELIVERY OF NON-VIRAL NUCLEIC ACID | MIRUS CORPORATION (US) | 2005-01-20 | — | — | WO | disclosed |
| US-20040019007-A1 | Intravascular delivery of non-viral nucleic acid | Arrowhead Madison Inc. | 2004-01-29 | — | — | US | disclosed |
| US-20020137707-A1 | Intravascular delivery of non-viral nucleic acid | MONAHAN SEAN D (US) | 2002-09-26 | — | — | US | disclosed |
| EP-1161547-A1 | INTRAVASCULAR DELIVERY OF NON-VIRAL NUCLEIC ACID | Mirus Corporation (US) | 2001-12-12 | — | — | EP | disclosed |
| WO-2000050617-A1 | INTRAVASCULAR DELIVERY OF NON-VIRAL NUCLEIC ACID | MIRUS CORPORATION (US) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019007-A1 | Intravascular delivery of non-viral nucleic acid | HNRNPH1, HNRNPA1, HNRNPH3 | ALDH1A1 4645/4885KDM4E 4775/4885SMN1; SMN2 577/4885 |
| US-20020137707-A1 | Intravascular delivery of non-viral nucleic acid | NSUN2, NCL, SLC29A1 | ALDH1A1 4655/4885KDM4E 4793/4885SMN1; SMN2 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.